LNK01004

LNK01004 is a topical, skin-restricted, soft pan-Janus kinase (JAK) inhibitor developed by Lynk Pharmaceuticals. It is designed to inhibit multiple inflammatory cytokines by targeting JAK1, JAK2, and TYK2 with high potency (IC50 values: JAK1 10 nM, JAK2 <0.51 nM, TYK2 1.0 nM). The drug is formulated as an ointment for topical application and demonstrates minimal systemic exposure due to its skin-restricted distribution. This property aims to reduce the risk of systemic side effects commonly associated with oral or injectable JAK inhibitors. LNK01004 has shown promising safety and efficacy in Phase 1b clinical trials for atopic dermatitis and plaque psoriasis, with no significant skin irritation or withdrawals reported during up to four weeks of treatment. Its mechanism allows it to potentially treat various immune-mediated dermatological conditions such as atopic dermatitis, psoriasis, and alopecia areata[1][5][7].